Home pageBSLN • SWX
add
Basilea Pharmaceutica Ltd.
Chiusura precedente
41,15 CHF
Intervallo giornaliero
40,60 CHF - 41,45 CHF
Intervallo annuale
32,00 CHF - 49,00 CHF
Cap di mercato
540,62 Mln CHF
Volume medio
17.179,00
Rapporto P/E
47,10
Dividendo/Prezzo
-
Borsa valori principale
SWX
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
| (CHF) | dic 2023info | Variazione Y/Y |
|---|---|---|
Entrate | 36,36 Mln | -19,30% |
Spese di gestione | 7,96 Mln | 12,34% |
Utile netto | -10,69 Mln | -187,82% |
Margine di profitto netto | -29,41 | -208,81% |
Utili per azione | — | — |
EBITDA | -7,88 Mln | -152,08% |
Aliquota fiscale effettiva | 0,08% | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (CHF) | dic 2023info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 59,93 Mln | -29,21% |
Totale attivo | 173,29 Mln | -21,53% |
Totale passivo | 183,29 Mln | -24,12% |
Patrimonio netto totale | -10,00 Mln | — |
Azioni in circolazione | 12,00 Mln | — |
Prezzo/valore contabile | -49,58 | — |
Redditività dell'attivo | -11,81% | — |
Rendimento sul capitale | -17,26% | — |
Flusso di cassa
Flusso di cassa netto
| (CHF) | dic 2023info | Variazione Y/Y |
|---|---|---|
Utile netto | -10,69 Mln | -187,82% |
Liquidità di esercizio | -3,81 Mln | -210,31% |
Contanti da investimenti | -322.500,00 | -100,69% |
Contanti da finanziamenti | -20,11 Mln | -4,52% |
Flusso di cassa netto | -24,31 Mln | -178,80% |
Flusso di cassa libero | -4,62 Mln | -154,24% |
Informazioni
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
CEO
Fondazione
ott 2000
Sito web
Dipendenti
147
